KeyBanc maintains Avanos Medical [AVNS]’s rating to Overweight and price target at 55

KeyBanc maintained its Avanos Medical [AVNS] rating to the equivalent of Overweight but changed the price target to $55 from $47, in a research note dated 2021-01-08. That figure represents around a 13.05% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Stifel’s analysts downgrading the shares from […]

Market Globalist
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.